Human monoclonal antibody and vaccine approaches to prevent human rabies

Current Topics in Microbiology and Immunology

Volumn 317, Issue , 2008, Pages 67-101

  Nagarajan, T ^a   Rupprecht, Charles E ^b   Dessain, Scott K ^c   Rangarajan, P N ^d   Thiagarajan, D ^a   Srinivasan, V A ^a  

^a Indian Immunologicals Limited   (India)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ABHAYRAB; DNA VACCINE; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN; RABIES VACCINE; RABIVAX; SAG 2 VACCINE; UNCLASSIFIED DRUG; VAXIRAB; VIRUS VACCINE; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

CLINICAL FEATURE; DISEASE CONTROL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; MORTALITY; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RABIES; RABIES VIRUS; REVIEW; VACCINATION; VIRUS IMMUNITY; VIRUS STRAIN; ANIMAL; DISEASE CARRIER; IMMUNOLOGY; VIROLOGY;

CRICETINAE; EQUIDAE; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; DISEASE RESERVOIRS; HUMANS; RABIES; RABIES VACCINES; VACCINES, DNA;

EID: 38449083228     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-72146-8_3     Document Type: Review

References (204)

1. Amengual B, Whitby JE, King A, Cobo JS, Bourhy H (1997) Evolution of European bat lyssaviruses. J Gen Virol 78:2319-2328
2. Arya SC (1991) Acquisition of spongiform encephalopathies in India through sheep-brain rabies vaccination. Indian J Pediatr 58:563-565
3. Aubert MF, Masson E, Artois M, Barrat J (1994) Oral wildlife rabies vaccination field trials in Europe, with recent emphasis on France. Curr Top Microbiol Immunol 187:219-243
4. Badrane H, Tordo N (2001) Host switching in Lyssavirus history from the Chiroptera to the Carnivora orders. J Virol 75:8096-8104
5. Badrane H, Bahloul C, Perrin P, Tordo N (2001) Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J Virol 75:3268-3276
6. Baer GM, Lentz TL (1991) Rabies pathogenesis in the central nervous system. In: Baer GM (ed) The natural history of rabies. CRC Press, Boca Raton, pp 105-120
7. Bahloul C, Jacob Y, Tordo N, Perrin P (1998) DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses. Vaccine 16:417-425
8. Bahloul C, Ahmed SB, B'Chir BI, Kharmachi H, Hayouni el A, Dellagi K (2003) Post-exposure therapy in mice against experimental rabies: a single injection of DNA vaccine is as effective as five injections of cell culture-derived vaccine. Vaccine 22:177-184
9. Bahloul C, Taieb D, Diouani MF, Ahmed SB, Chtourou Y, B'Chir BI, Kharmachi H, Dellagi K (2006) Field trials of a very potent rabies DNA vaccine which induced long lasting virus neutralizing antibodies and protection in dogs in experimental conditions. Vaccine 24:1063-1072
10. Bakker H, Bardor M, Molthoff JW, Gomord V, Elbers I, Stevens LH, Jordi W, Lommen A, Faye L, Lerouge P, Bosch D (2001) Galactose-extended glycans of antibodies produced by transgenic plants. Proc Natl Acad Sci U S A 98:2899-2904
11. Balthazard M, Bhamanyar M, Ghodssi M, Sabeti A, Gajdusek C, Rouzbehi E (1955) Essai pratique du serum antirabique chez les mordus par loups enrages. Bull World Health Organ 13:747-772
12. Barth R, Gruschkau H, Bijok U, Hilfenhaus J, Hinz J, Milcke L, Moser H, Jaeger O, Ronneberger H, Weinmann E (1984) A new inactivated tissue culture rabies vaccine for use in man. Evaluation of PCEC-vaccine by laboratory tests. J Biol Stand 12:29-46
13. Belotto A, Leanes LF, Schneider MC, Tamayo H, Correa E (2005) Overview of rabies in the Americas. Virus Res 111:5-12
14. Benmansour A, Leblois H, Coulon P, Tuffereau C, Gaudin Y, Flamand A, Lafay F (1991) Antigenicity of rabies virus glycoprotein. J Virol 65:4198-4203
15. Bhatia R, Ichhpujani RL, Madhusudana SN, Hemachudha T (2004) Rabies in South and Southeast Asia. In: Program and abstracts of the WHO Expert Consultation on Rabies, Geneva
16. Biswas S, Reddy GS, Srinivasan VA, Rangarajan PN (2001) Preexposure efficacy of a novel combination DNA and inactivated rabies virus vaccine. Hum Gene Ther 12:1917-1922
17. Blancou J (1988) Ecology and epidemiology of fox rabies. Rev Infect Dis 10 [Suppl 4]: S606-S609
18. Bogel K, Motschwiller E (1986) Incidence of rabies and post-exposure treatment in developing countries. Bull World Health Organ 64:883-887
19. Bourhy H, Kissi B, Lafon M, Sacramento D, Tordo N (1992) Antigenic and molecular characterization of bat rabies virus in Europe. J Clin Microbiol 30:2419-2426
20. Bourhy H, Kissi B, Tordo N (1993) Molecular diversity of the Lyssavirus genus. Virology 194:70-81
21. Bregenholt S, Haurum J (2004) Pathogen-specific recombinant human polyclonal antibodies: biodefence applications. Expert Opin Biol Ther 4:387-396
22. Brekke OH, Sandlie I (2003) Therapeutic antibodies for human diseases at the dawn of the twentyfirst century. Nat Rev Drug Discov 2:52-62
23. Briggs DJ, Banzhoff A, Nicolay U, Sirikwin S, Dumavibhat B, Tongswas S, Wasi C (2000) Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 78:693-698
24. Brookes SM, Parsons G, Johnson N, McElhinney LM, Fooks AR (2005) Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. Vaccine 23:4101-4109
25. Carroll WL, Thielemans K, Dilley J, Levy R (1986) Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods 89:61-72
26. Casadevall A (2002) Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis 8:833-841
27. Center for Biologics Evaluation and Research (1995) Guidance for industry: considerations for plasmid DNA vaccines for infectious disease indications. http://www.fda.gov/cber/gdlns/plasdnavac. pdf. Cited 18 May 2007
28. Centers for Disease Control and Prevention (1999) Human rabies prevention - United States, 1999. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 48:1-21
29. Centers for Disease Control (2004) Manufacturer's recall of human rabies vaccine. MMWR Dispatch 53:287-289
30. Champion JM, Kean RB, Rupprecht CE, Notkins AL, Koprowski H, Dietzschold B, Hooper DC (2000) The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J Immunol Methods 235:81-90
31. Cheung SC, Dietzschold B, Koprowski H, Notkins AL, Rando RF (1992) A recombinant human Fab expressed in Escherichia coli neutralizes rabies virus. J Virol 66:6714-6720
32. Childs JE, Curns AT, Dey ME, Real LA, Feinstein L, Bjornstad ON, Krebs JW (2000) Predicting the local dynamics of epizootic rabies among raccoons in the United States. Proc Natl Acad Sci U S A 97:13666-13671
33. Chin J (2000) Control of communicable diseases manual. APHA, Washington, DC
34. Chutivongse S, Wilde H, Supich C, Baer GM, Fishbein DB (1990) Postexposure prophylaxis for rabies with antiserum and intradermal vaccination. Lancet 335:896-898
35. Chutivongse S, Wilde H, Fishbein DB, Baer GM, Hemachudha T (1991) One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine. Vaccine 9:573-576
36. Cleaveland S, Kaare M, Tiringa P, Mlengeya T, Barrat J (2003) A dog rabies vaccination campaign in rural Africa: impact on the incidence of dog rabies and human dog-bite injuries. Vaccine 21:1965-1973
37. Cliquet F, Aubert M, Sagne L (1998) Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J Immunol Methods 212:79-87
38. Coleman PG, Fevre EM, Cleaveland S (2004) Estimating the public health impact of rabies. Emerg Infect Dis 10:140-142
39. Corn JL, Mendez JR, Catalan EE (2003) Evaluation of baits for delivery of oral rabies vaccine to dogs in Guatemala. Am J Trop Med Hyg 69:155-158
40. Cox JH, Dietzschold B, Schneider LG (1977) Rabies virus glycoprotein. II. Biological and serological characterization. Infect Immun 16:754-759
41. Daniell H, Streatfield SJ, Wycoff K (2001) Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci 6:219-226
42. David D, Yakobson BA, Gershkovich L, Gayer S (2004) Tracing the regional source of rabies infection in an Israeli dog by viral analysis. Vet Rec 155:496-497
43. de Kruif J, Bakker AB, Marissen WE, Kramer RA, Throsby M, Rupprecht CE, Goudsmit J (2007) A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 58:359-368
44. Dean DJ, Baer GM, Thompson WR (1963) Studies on the local treatment of rabies-infected wounds. Bull World Health Organ 28:477-486
45. Dietzschold B, Schnell MJ (2002) New approaches to the development of live attenuated rabies vaccines. Hybrid Hybridomics 21:129-134
46. Dietzschold B, Tollis M, Lafon M, Wunner WH, Koprowski H (1987) Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies. Virology 161:29-36
47. Dietzschold B, Gore M, Casali P, Ueki Y, Rupprecht CE, Notkins AL, Koprowski H (1990) Biological characterization of human monoclonal antibodies to rabies virus. J Virol 64: 3087-3090
48. Dietzschold B, Kao M, Zheng YM, Chen ZY, Maul G, Fu ZF, Rupprecht CE, Koprowski H (1992) Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc Natl Acad Sci U S A 89:7252-7256
49. Dietzschold B, Faber M, Schnell MJ (2003) New approaches to the prevention and eradication of rabies. Expert Rev Vaccines 2:399-406
50. Dreesen DW, Fishbein DB, Kemp DT, Brown J (1989) Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization. Vaccine 7:397-400
51. Enssle K, Kurrle R, Kohler R, Muller H, Kanzy EJ, Hilfenhaus J, Seiler FR (1991) A rabies-specific human monoclonal antibody that protects mice against lethal rabies. Hybridoma 10:547-556
52. Ertl HC (2005) Immunological insights from genetic vaccines. Virus Res 111:89-92
53. Ertl HC, Xiang ZQ (1996) Genetic immunization. Viral Immunol 9:1-9
54. Estrada R, Vos A, De Leon R, Mueller T (2001) Field trial with oral vaccination of dogs against rabies in the Philippines. BMC Infect Dis 1:23
55. Farrugia A, Poulis P (2001) Intravenous immunoglobulin: regulatory perspectives on use and supply. Transfus Med 11:63-74
56. Fu ZF (1997) Rabies and rabies research: past, present and future. Vaccine 15 Suppl:S20-S24
57. Fuenzalida E, Palacios R (1955) An improved method for preparation of rabies vaccine [in Spanish]. Biol Inst Bacteriol Chile 8:3-10
58. Funaro A, Horenstein AL, Ghisolfi G, Bussolati B, Bartorelli A, Bussolati G (1999) Identification of a 220-kDa membrane tumor-associated antigen by human anti-UK114 monoclonal antibodies selected from the immunoglobulin repertoire of a cancer patient. Exp Cell Res 247:441-450
59. Girard LS, Fabis MJ, Bastin M, Courtois D, Petiard V, Koprowski H (2006) Expression of a human anti-rabies virus monoclonal antibody in tobacco cell culture. Biochem Biophys Res Commun 345:602-607
60. Goudsmit J, Marissen WE, Weldon WC, Niezgoda M, Hanlon CA, Rice AB, Kruif J, Dietzschold B, Bakker AB, Rupprecht CE (2006) Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 193:796-801
61. Haddad N, Ben Khelifa R, Matter H, Kharmachi H, Aubert MF, Wandeler A, Blancou J (1994) Assay of oral vaccination of dogs against rabies in Tunisia with the vaccinal strain SADBern. Vaccine 12:307-309
62. Hanlon CA, Niezgoda M, Morrill PA, Rupprecht CE (2001) The incurable wound revisited: progress in human rabies prevention? Vaccine 19:2273-2279
63. Hassett DE, Whitton JL (1996) DNA immunization. Trends Microbiol 4:307-312
64. Hattwick MA, Corey L, Creech WB (1976) Clinical use of human globulin immune to rabies virus. J Infect Dis 133 Suppl:A266-272
65. Haurum J, Bregenholt S (2005) Recombinant polyclonal antibodies: therapeutic antibody technologies come full circle. IDrugs 8:404-409
66. Hellwig S, Drossard J, Twyman RM, Fischer R (2004) Plant cell cultures for the production of recombinant proteins. Nat Biotechnol 22:1415-1422
67. Hemachudha T (1989) Rabies. In: Vinken PJ, Bruyn GW, Klawans HL, McKendall RR (eds) Viral disease. Elsevier, Amsterdam, pp 383-404
68. Hemachudha T (1994) Human rabies: clinical aspects, pathogenesis, and potential therapy. Curr Top Microbiol Immunol 187:121-143
69. Hemachudha T, Mitrabhakdi E (2000) Rabies. In: Davis LE, Kennedy PGE (eds) Infectious diseases of the nervous system. Butterworth Heinemann, Oxford, pp 401-444
70. Hemachudha T, Phuapradit P (1997) Rabies. Curr Opin Neurol 10:260-267
71. Hemachudha T, Phanuphak P, Johnson RT, Griffin DE, Ratanavongsiri J, Siriprasomsup W (1987) Neurologic complications of Semple-type rabies vaccine: clinical and immunologic studies. Neurology 37:550-556
72. Hemachudha T, Laothamatas J, Rupprecht CE (2002) Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges. Lancet Neurol 1:101-109
73. Hiatt A, Cafferkey R, Bowdish K (1989) Production of antibodies in transgenic plants. Nature 342:76-78
74. Holmes EC, Woelk CH, Kassis R, Bourhy H (2002) Genetic constraints and the adaptive evolution of rabies virus in nature. Virology 292:247-257
75. Hooper DC, Morimoto K, Bette M, Weihe E, Koprowski H, Dietzschold B (1998) Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J Virol 72:3711-3719
76. Hooper PT, Lunt RA, Gould AR, Samaratunga H, Hyatt AD, Gleeson LJ, Rodwell BJ, Rupprecht CE, Smith JS, Murray PK (1997) A new lyssavirus-the first endemic rabies-related virus recognized in Australia. Bull Inst Pasteur 95:209-218
77. Ichhpujani RL, Bhardwaj M, Chhabra M, Datta KK (2001) Rabies in humans in India. In: Dodet B, Meslin FX, Haseltine E (eds) Proceedings of the fourth international symposium on rabies control in Asia. John Libbey Eurotext, London, pp 212-213
78. Ito M, Itou T, Shoji Y, Sakai T, Ito FH, Arai YT, Takasaki T, Kurane I (2003) Discrimination between dog-related and vampire bat-related rabies viruses in Brazil by strain-specific reverse transcriptase-polymerase chain reaction and restriction fragment length polymorphism analysis. J Clin Virol 26:317-330
79. Jallet C, Jacob Y, Bahloul C, Drings A, Desmezieres E, Tordo N, Perrin P (1999) Chimeric lyssavirus glycoproteins with increased immunological potential. J Virol 73:225-233
80. Jenkins SR, Perry BD, Winkler WG (1988) Ecology and epidemiology of raccoon rabies. Rev Infect Dis 10 [Suppl 4]:S620-S625
81. Jenkins SR, Auslander M, Conti L, Leslie MJ, Sorhage FE, Sun B (2004) Compendium of animal rabies prevention and control, 2004. J Am Vet Med Assoc 224:216-222
82. Kallel H, Diouani MF, Loukil H, Trabelsi K, Snoussi MA, Majoul S, Rourou S, Dellagi K (2006) Immunogenicity and efficacy of an in-house developed cell-culture derived veterinarian rabies vaccine. Vaccine 24:4856-4862
83. Khawplod P, Wilde H, Chomchey P, Benjavongkulchai M, Yenmuang W, Chaiyabutr N, Sitprija V (1996) What is an acceptable delay in rabies immune globulin administration when vaccine alone had been given previously? Vaccine 14:389-391
84. Kilic B, Unal B, Semin S, Konakci SK (2006) An important public health problem: rabies suspected bites and post-exposure prophylaxis in a health district in Turkey. Int J Infect Dis 10:248-254
85. Kitala PM, McDermott JJ, Kyule MN, Gathuma JM (2000) Community-based active surveillance for rabies in Machakos District, Kenya. Prev Vet Med 44:73-85
86. Knobel DL, Cleaveland S, Coleman PG, Fevre EM, Meltzer MI, Miranda ME, Shaw A, Zinsstag J, Meslin FX (2005) Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 83:360-368
87. Ko K, Tekoah Y, Rudd PM, Harvey DJ, Dwek RA, Spitsin S, Hanlon CA, Rupprecht C, Dietzschold B, Golovkin M, Koprowski H (2003) Function and glycosylation of plant-derived antiviral monoclonal antibody. Proc Natl Acad Sci U S A 100:8013-8018
88. Koprowski H, Van Der Scheer J, Black J (1950) Use of hyperimmune anti-rabies serum concentrates in experimental rabies. Am J Med 8:412-420
89. Koprowski H, Wiktor T, Abelseth M (1985) Cross-reactivity and cross-protection: rabies variants and rabies-related viruses. In: Kuwert E, Merieux C, Koprowski H, Bogel K (eds) Rabies in the tropics. Springer-Verlag, Berlin Heidelberg New York, pp 30-39
90. Kramer RA, Marissen WE, Goudsmit J, Visser TJ, Clijsters-Van der Horst M, Bakker AQ, de Jong M, Jongeneelen M, Thijsse S, Backus HH, Rice AB, Weldon WC, Rupprecht CE, Dietzschold B, Bakker AB, de Kruif J (2005) The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol 35:2131-2145
91. Krebs JW, Mandel EJ, Swerdlow DL, Rupprecht CE (2005) Rabies surveillance in the United States during 2004. J Am Vet Med Assoc 227:1912-1925
92. Kureishi A, Xu LZ, Wu H, Stiver HG (1992) Rabies in China: recommendations for control. Bull World Health Organ 70:443-450
93. Kuzmin IV, Hughes GJ, Botvinkin AD, Orciari LA, Rupprecht CE (2005) Phylogenetic relationships of Irkut and West Caucasian bat viruses within the Lyssavirus genus and suggested quantitative criteria based on the N gene sequence for Lyssavirus genotype definition. Virus Res 111:28-43
94. Lafon M, Edelman L, Bouvet JP, Lafage M, Montchatre E (1990) Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein. J Gen Virol 71:1689-1696
95. Lerouge P, Bardor M, Pagny S, Gomord V, Faye L (2000) N-Glycosylation of recombinant pharmaceutical glycoproteins produced in transgenic plants: towards an humanisation of plant N-glycans. Curr Pharm Biotechnol 1:347-354
96. Liang M, Dubel S, Li D, Queitsch I, Li W, Bautz EK (2001) Baculovirus expression cassette vectors for rapid production of complete human IgG from phage display selected antibody fragments. J Immunol Methods 247:119-130
97. Libeau G, Lafon M (1984) Production of monoclonal antibodies against the Pasteur (P.V.) strain of rabies virus: problems and results. Dev Biol Stand 57:213-218
98. Lodmell DL, Ewalt LC (2001) Post-exposure DNA vaccination protects mice against rabies virus. Vaccine 19:2468-2473
99. Lodmell DL, Ray NB, Parnell MJ, Ewalt LC, Hanlon CA, Shaddock JH, Sanderlin DS, Rupprecht CE (1998) DNA immunization protects nonhuman primates against rabies virus. Nat Med 4:949-952
100. Lodmell DL, Ray NB, Ulrich JT, Ewalt LC (2000) DNA vaccination of mice against rabies virus: effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL). Vaccine 18:1059-1066
101. Lodmell DL, Parnell MJ, Bailey JR, Ewalt LC, Hanlon CA (2001) One-time gene gun or intramuscular rabies DNA vaccination of non-human primates: comparison of neutralizing antibody responses and protection against rabies virus 1 year after vaccination. Vaccine 20:838-844
102. Ma JK, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, Yu L, Hein MB, Lehner T (1998) Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat Med 4:601-606
103. MacInnes CD, Smith SM, Tinline RR, Ayers NR, Bachmann P, Ball DG, Calder LA, Crosgrey SJ, Fielding C, Hauschildt P, Honig JM, Johnston DH, Lawson KF, Nunan CP, Pedde MA, Pond B, Stewart RB, Voigt DR (2001) Elimination of rabies from red foxes in eastern Ontario. J Wildl Dis 37:119-132
104. Marissen WE, Kramer RA, Rice A, Weldon WC, Niezgoda M, Faber M, Slootstra JW, Meloen RH, Clijsters-van der Horst M, Visser TJ, Jongeneelen M, Thijsse S, Throsby M, de Kruif J, Rupprecht CE, Dietzschold B, Goudsmit J, Bakker AB (2005) Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J Virol 79:4672-4678
105. Martinez L (2000) Global infectious disease surveillance. Int J Infect Dis 4:222-228
106. Matha IS, Salunke SR (2005) Immunogenicity of purified vero cell rabies vaccine used in the treatment of fox-bite victims in India. Clin Infect Dis 40:611-613
107. May RM, Anderson RM (1984) Spatial heterogeneity and the design of immunization programs. Math Biosci 72:83-111
108. Mayen F (2003) Haematophagous bats in Brazil, their role in rabies transmission, impact on public health, livestock industry and alternatives to an indiscriminate reduction of bat population. J Vet Med B Infect Dis Vet Public Health 50:469-472
109. McKay N, Wallis L (2005) Rabies: a review of UK management. Emerg Med J 22:316-321
110. Mebatsion T, Weiland F, Conzelmann KK (1999) Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. J Virol 73:242-250
111. Meslin FX, Kaplan MM (1996) General considerations in the production and use of brain-tissue and purified chicken embryo rabies vaccines for human use. In: Meslin FX, Kaplan MM, koprowski H (eds) Laboratory techniques in rabies. WHO, Geneva, pp 221-233
112. Meslin FX, Fishbein DB, Matter HC (1994) Rationale and prospects for rabies elimination in developing countries. Curr Top Microbiol Immunol 187:1-26
113. Messenger SL, Smith JS, Rupprecht CE (2002) Emerging epidemiology of bat-associated cryptic cases of rabies in humans in the United States. Clin Infect Dis 35:738-747
114. Mitmoonpitak C, Tepsumethanon V, Wilde H (1998) Rabies in Thailand. Epidemiol Infect 120:165-169
115. Montagnon B, Vincent-Falquet JC, Fanget B (1983) Thousand litre scale microcarrier culture of Vero cells for killed polio virus vaccine. Promising results. Dev Biol Stand 55:37-42
116. Morimoto K, Patel M, Corisdeo S, Hooper DC, Fu ZF, Rupprecht CE, Koprowski H, Dietzschold B (1996) Characterization of a unique variant of bat rabies virus responsible for newly emerging human cases in North America. Proc Natl Acad Sci U S A 93:5653-5658
117. Morimoto K, McGettigan JP, Foley HD, Hooper DC, Dietzschold B, Schnell MJ (2001a) Genetic engineering of live rabies vaccines. Vaccine 19:3543-3551
118. Morimoto K, Schnell MJ, Pulmanausahakul R, McGettigan JP, Foley HD, Faber M, Hooper DC, Dietzschold B (2001b) High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector. J Immunol Methods 252:199-206
119. Mudur G (2005) Foreign visitors to India are unaware of rabies risk. BMJ 331:255
120. Muller BH, Lafay F, Demangel C, Perrin P, Tordo N, Flamand A, Lafaye P, Guesdon JL (1997) Phage-displayed and soluble mouse scFv fragments neutralize rabies virus. J Virol Methods 67:221-233
121. Nadin-Davis SA, Abdel-Malik M, Armstrong J, Wandeler AI (2002) Lyssavirus P gene characterisation provides insights into the phylogeny of the genus and identifies structural similarities and diversity within the encoded phosphoprotein. Virology 298:286-305
122. Nagarajan T, Mohanasubramanian B, Seshagiri EV, Nagendrakumar SB, Saseendranath MR, Satyanarayana ML, Thiagarajan D, Rangarajan PN, Srinivasan VA (2006a) Molecular epidemiology of rabies virus isolates in India. J Clin Microbiol 44:3218-3224
123. Nagarajan T, Reddy GS, Mohana Subramanian B, Rajalakshmi S, Thiagarajan D, Tordo N, Jallet C, Srinivasan VA (2006b) A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture. Biologicals 34:21-27
124. Nel LH, Sabeta CT, von Teichman B, Jaftha JB, Rupprecht CE, Bingham J (2005) Mongoose rabies in southern Africa: a re-evaluation based on molecular epidemiology. Virus Res 109:165-173
125. Nicholson KG (1996) Cell-culture vaccines for human use: general considerations. In: Meslin FX, Kaplan MM, Koprowski H (eds) Laboratory techniques in rabies. WHO, Geneva, pp 271-279
126. Nishizono A, Mannen K, Elio-Villa LP, Tanaka S, Li KS, Mifune K, Arca BF, Cabanban A, Martinez B, Rodriguez A, Atienza VC, Camba R, Resontoc N (2002) Genetic analysis of rabies virus isolates in the Philippines. Microbiol Immunol 46:413-417
127. Owens RJ, Young RJ (1994) The genetic engineering of monoclonal antibodies. J Immunol Methods 168:149-165
128. Parviz S, Luby S, Wilde H (1998) Postexposure treatment of rabies in Pakistan. Clin Infect Dis 27:751-756
129. Pasquini S, Deng H, Reddy ST, Giles-Davis W, Ertl HC (1999) The effect of CpG sequences on the B cell response to a viral glycoprotein encoded by a plasmid vector. Gene Ther 6:1448-1455
130. Patrick GR, O'Rourke KM (1998) Dog and cat bites: epidemiologic analyses suggest different prevention strategies. Public Health Rep 113:252-257
131. Perera MA, Harischandra PA, Wimalaratne O, Damboragama SN (2000) Feasibility of canine oral rabies vaccination in Sri Lanka-a preliminary report. Ceylon Med J 45:61-64
132. Perrin P, Madhusudana S, Gontier-Jallet C, Petres S, Tordo N, Merten OW (1995) An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serumfree medium and perfusion-reactor system. Vaccine 13:1244-1250
133. Perrin P, Jacob Y, Aguilar-Setien A, Loza-Rubio E, Jallet C, Desmezieres E, Aubert M, Cliquet F, Tordo N (1999) Immunization of dogs with a DNA vaccine induces protection against rabies virus. Vaccine 18:479-486
134. Pinto AR, Reyes-Sandoval A, Ertl HC (2003) Chemokines and TRANCE as genetic adjuvants for a DNA vaccine to rabies virus. Cell Immunol 224:106-113
135. Plotkin SA (1980) Rabies vaccine prepared in human cell cultures: progress and perspectives. Rev Infect Dis 2:433-448
136. Plotkin SA, Rupprecht CE, Koprowski H (1999) Rabies vaccine. In: Plotkin SA, Orenstein WA (eds) Vaccines. WB Saunders, Philadelphia, pp 743-766
137. Prehaud C, Coulon P, LaFay F, Thiers C, Flamand A (1988) Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence. J Virol 62:1-7
138. Prosniak M, Faber M, Hanlon CA, Rupprecht CE, Hooper DC, Dietzschold B (2003) Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J Infect Dis 188:53-56
139. Ramanna BC, Reddy GS, Srinivasan VA (1991) An outbreak of rabies in cattle and use of tissue culture rabies vaccine during the outbreak. J Commun Dis 23:283-285
140. Rath A, Choudhury S, Batra D, Kapre SV, Rupprecht CE, Gupta SK (2005) DNA vaccine for rabies: relevance of the transmembrane domain of the glycoprotein in generating an antibody response. Virus Res 113:143-152
141. Ray NB, Ewalt LC, Lodmell DL (1997) Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection. Vaccine 15:892-895
142. Real LA, Henderson JC, Biek R, Snaman J, Jack TL, Childs JE, Stahl E, Waller L, Tinline R, Nadin-Davis S (2005) Unifying the spatial population dynamics and molecular evolution of epidemic rabies virus. Proc Natl Acad Sci U S A 102:12107-12111
143. Rotz LD, Hensley JA, Rupprecht CE, Childs JE (1998) Large-scale human exposures to rabid or presumed rabid animals in the United States: 22 cases (1990-1996). J Am Vet Med Assoc 212:1198-1200
144. Rupprecht CE, Gibbons RV (2004) Clinical practice. Prophylaxis against rabies. N Engl J Med 351:2626-2635
145. Rupprecht CE, Charlton KM, Artois M, Casey GA, Webster WA, Campbell JB, Lawson KF, Schneider LG (1990) Ineffectiveness and comparative pathogenicity of attenuated rabies virus vaccines for the striped skunk (Mephitis mephitis). J Wildl Dis 26:99-102
146. Rupprecht CE, Hanlon CA, Cummins LB, Koprowski H (1992) Primate responses to a vacciniarabies glycoprotein recombinant virus vaccine. Vaccine 10:368-374
147. Rupprecht CE, Hanlon CA, Hemachudha T (2002) Rabies re-examined. Lancet Infect Dis 2:327-343
148. Rupprecht CE, Hanlon CA, Blanton J, Manangan J, Morrill P, Murphy S, Niezgoda M, Orciari LA, Schumacher CL, Dietzschold B (2005) Oral vaccination of dogs with recombinant rabies virus vaccines. Virus Res 111:101-105
149. Sampath G, Reddy SV, Rao ML, Rao YU, Palaniappan C (2005) An immunogenicity study of a newly introduced purified Vero cell rabies vaccine (Abhayrab) manufactured in India. Vaccine 23:897-900
150. Schumacher CL, Dietzschold B, Ertl HC, Niu HS, Rupprecht CE, Koprowski H (1989) Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies. J Clin Invest 84:971-975
151. Servat A, Lutsch C, Delore V, Lang J, Veitch K, Cliquet F (2003) Efficacy of rabies immunoglobulins in an experimental post-exposure prophylaxis rodent model. Vaccine 22: 244-249
152. Shah U, Jaswal GS (1975) Follow-up of rabid dog bite victims. Lancet 2:653-655
153. Shetty RA, Chaturvedi S, Singh Z (2005) Profile of animal bite cases in Pune. J Commun Dis 37:66-72
154. Siemoneit K, da Silva Cardoso M, Wolpl A, Koerner K, Subanek B (1994) Isolation and epitope characterization of human monoclonal antibodies to hepatitis C virus core antigen. Hybridoma 13:9-13
155. Sikes RK, Peacock GV, Acha P, Arko RJ, Dierks R (1971) Rabies vaccines: duration-of-immunity study in dogs. J Am Vet Med Assoc 159:1491-1499
156. Sitthi-Amorn C, Jiratanavattana V, Keoyoo J, Sonpunya N (1987) The diagnostic properties of laboratory tests for rabies. Int J Epidemiol 16:602-605
157. Slade HB (1994) Human immunoglobulins for intravenous use and hepatitis C viral transmission. Clin Diagn Lab Immunol 1:613-619
158. Smith JS, Fishbein DB, Rupprecht CE, Clark K (1991) Unexplained rabies in three immigrants in the United States. A virologic investigation. N Engl J Med 324:205-211
159. Steck F, Wandeler A, Bichsel P, Capt S, Hafliger U, Schneider L (1982) Oral immunization of foxes against rabies. Laboratory and field studies. Comp Immunol Microbiol Infect Dis 5:165-171
160. Steele JH (1988) Rabies in the Americas and remarks on global aspects. Rev Infect Dis 10 [Suppl 4]: S585-597
161. Stoger E, Sack M, Nicholson L, Fischer R, Christou P (2005) Recent progress in plantibody technology. Curr Pharm Des 11:2439-2457
162. Stohr K, Meslin FM (1996) Progress and setbacks in the oral immunisation of foxes against rabies in Europe. Vet Rec 139:32-35
163. Strady A, Lang J, Rotivel Y, Jaussaud R, Fritzell C, Tsiang H (1996) [Immunoprophylaxis of rabies: current recommendations]. Presse Med 25:1023-1027
164. Sudarshan MK, Mahendra BJ, Narayan DH (2001) A community survey of dog bites, anti-rabies treatment, rabies and dog population management in Bangalore city. J Commun Dis 33:245-251
165. Sudarshan MK, Madhusudana SN, Mahendra BJ, Rao NS, Ashwath Narayana DH, Abdul Rahman S, Meslin FX, Lobo D, Ravikumar K, Gangaboraiah (2007) Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int J Infect Dis 11:29-35
166. Suntharasamai P, Chaiprasithikul P, Wasi C, Supanaranond W, Auewarakul P, Chanthavanich P, Supapochana A, Areeraksa S, Chittamas S, Jittapalapongsa S, et al (1994) A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for postexposure prophylaxis. Vaccine 12:508-512
167. Swaddiwuthipong W, Weniger BG, Wattanasri S, Warrell MJ (1988) A high rate of neurological complications following Semple anti-rabies vaccine. Trans R Soc Trop Med Hyg 82: 472-475
168. Taylor LH, Latham SM, Woolhouse ME (2001) Risk factors for human disease emergence. Philos Trans R Soc Lond B Biol Sci 356:983-989
169. Tollis M, Dietzschold B, Volia CB, Koprowski H (1991) Immunization of monkeys with rabies ribonucleoprotein (RNP) confers protective immunity against rabies. Vaccine 9:134-136
170. Tordo N, Poch O, Ermine A, Keith G, Rougeon F (1986) Walking along the rabies genome: is the large G-L intergenic region a remnant gene? Proc Natl Acad Sci U S A 83:3914-3918
171. Trabelsi K, Rourou S, Loukil H, Majoul S, Kallel H (2006) Optimization of virus yield as a strategy to improve rabies vaccine production by Vero cells in a bioreactor. J Biotechnol 121:261-271
172. Ueki Y, Goldfarb IS, Harindranath N, Gore M, Koprowski H, Notkins AL, Casali P (1990) Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J Exp Med 171:19-34
173. Ulmer JB, Liu MA (2002) Ethical issues for vaccines and immunization. Nat Rev Immunol 2:291-296
174. Velasco-Villa A, Orciari LA, Souza V, Juarez-Islas V, Gomez-Sierra M, Castillo A, Flisser A, Rupprecht CE (2005) Molecular epizootiology of rabies associated with terrestrial carnivores in Mexico. Virus Res 111:13-27
175. Velasco-Villa A, Orciari LA, Juarez-Islas V, Gomez-Sierra M, Padilla-Medina I, Flisser A, Souza V, Castillo A, Franka R, Escalante-Mane M, Sauri-Gonzalez I, Rupprecht CE (2006) Molecular diversity of rabies viruses associated with bats in Mexico and other countries of the Americas. J Clin Microbiol 44:1697-1710
176. Wandeler A (2004) Epidemiology and ecology of fox rabies in Europe. In: King AA, Fooks AR, Aubert M, Wandeler A (eds) Historical perspective of rabies in Europe and the Mediterranean basin. OIE, Paris, pp 201-214
177. Wandeler AI, Budde A, Capt S, Kappeler A, Matter H (1988) Dog ecology and dog rabies control. Rev Infect Dis 10 [Suppl 4]:S684-S688
178. Wandeler AI, Matter HC, Kappeler A, Budde A (1993) The ecology of dogs and canine rabies: a selective review. Rev Sci Tech 12:51-71
179. Wang Y, Xiang Z, Pasquini S, Ertl HC (1997) Immune response to neonatal genetic immunization. Virology 228:278-284
180. Wang Y, Xiang Z, Pasquini S, Ertl HC (1998) Effect of passive immunization or maternally transferred immunity on the antibody response to a genetic vaccine to rabies virus. J Virol 72:1790-1796
181. Warrell MJ, Nicholson KG, Warrell DA, Suntharasamai P, Chanthavanich P, Viravan C, Sinhaseni A, Chiewbambroongkiat MK, Pouradier-Duteil X, Xueref C, et al (1985) Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for postexposure rabies prophylaxis. Lancet 1:1059-1062
182. Whitelam GC, Cockburn W, Owen MR (1994) Antibody production in transgenic plants. Biochem Soc Trans 22:940-944
183. WHO (1993) Report of the fourth WHO consultation on oral immunization of dogs against rabies. WHO, Geneva. http://www.who.int/rabies/animal/en/ whorabres9342.pdf. Cited 18 May 2007
184. WHO (1996) WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization. WHO, Geneva. http://whqlibdoc. who.int/hq/1996/WHO-EMC-ZOO-96.6.pdf. Cited 18 May 2007
185. WHO (1998) World survey of rabies No 32 for the Year 1996. WHO, Geneva. http://whqlibdoc. who.int/hq/1998/WHO-EMC-ZDI-98.4.pdf. Cited 18 May 2007
186. WHO (2001) Strategies for the control and elimination of rabies in Asia. WHO, Geneva. http:// www.who.int/rabies/en/Strategies-for-the-control-and- elimination-of-rabies-in-Asia.pdf. Cited 18 May 2007
187. WHO (2002a) Rabies vaccines. Wkly Epidemiol Rec 77:109-119
188. WHO (2002b) World Survey of Rabies No 35 for the Year 1999. WHO, Geneva. http://www.who. int/rabies/resources/wsr1999/en/index.html. Cited 18 May 2007
189. WHO (2004) WHO expert consultation on rabies. First report, WHO technical report series 931. WHO, Geneva, p 121
190. WHO (2006) Rabies fact sheet No 99. WHO, Geneva. http://www.who.int/ mediacentre/factsheets/ fs099/en/print.html. Cited 18 May 2007
191. WHO-APCRI (2004) Assessing burden of rabies in India. WHO, Geneva. http://www.apcri.org/ whosurvey.pdf. Cited 18 May 2007
192. Wiktor TJ, Koprowski H (1978) Monoclonal antibodies against rabies virus produced by somatic cell hybridization: detection of antigenic variants. Proc Natl Acad Sci U S A 75:3938-3942
193. Wiktor TJ, Sokol F, Kuwert E, Koprowski H (1969) Immunogenicity of concentrated and purified rabies vaccine of tissue culture origin. Proc Soc Exp Biol Med 131:799-805
194. Wilde H, Choomkasien P, Hemachudha T, Supich C, Chutivongse S (1989) Failure of rabies post-exposure treatment in Thailand. Vaccine 7:49-52
195. Wilde H, Sirikawin S, Sabcharoen A, Kingnate D, Tantawichien T, Harischandra PA, Chaiyabutr N, de Silva DG, Fernando L, Liyanage JB, Sitprija V (1996) Failure of postexposure treatment of rabies in children. Clin Infect Dis 22:228-232
196. Wilde H, Khawplod P, Hemachudha T, Sitprija V (2002) Postexposure treatment of rabies infection: can it be done without immunoglobulin? Clin Infect Dis 34:477-480
197. Wilde H, Khawplod P, Khamoltham T, Hemachudha T, Tepsumethanon V, Lumlerdacha B, Mitmoonpitak C, Sitprija V (2005) Rabies control in South and Southeast Asia. Vaccine 23:2284-2289
198. Willoughby RE Jr, Tieves KS, Hoffman GM, Ghanayem NS, Amlie-Lefond CM, Schwabe MJ, Chusid MJ, Rupprecht CE (2005) Survival after treatment of rabies with induction of coma. N Engl J Med 352:2508-2514
199. Winkler WG, Bogel K (1992) Control of rabies in wildlife. Sci Am 266:86-92
200. Wunner WH (2002) Rabies virus. In: Jackson AC, Wunner WH (eds) Rabies. Academic Press, San Diego, pp 23-77
201. Wunner WH, Larson JK, Dietzschold B, Smith CL (1988) The molecular biology of rabies viruses. Rev Infect Dis 10 [Suppl 4]:S771-S784
202. Xiang ZQ, Spitalnik S, Tran M, Wunner WH, Cheng J, Ertl HC (1994) Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology 199:132-140
203. Xiang ZQ, Spitalnik SL, Cheng J, Erikson J, Wojczyk B, Ertl HC (1995) Immune responses to nucleic acid vaccines to rabies virus. Virology 209:569-579
204. Yusibov V, Hooper DC, Spitsin SV, Fleysh N, Kean RB, Mikheeva T, Deka D, Karasev A, Cox S, Randall J, Koprowski H (2002) Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 20:3155-3164